Liferna unlocks the full potential of innovative therapeutic programs through focused development strategies, global collaboration, and a commitment to better treatment options worldwide.
Innovative science has the potential to change patients' lives — and we are committed to making that a reality.
We advance innovative therapeutic programs through focused development strategies, global collaboration, and a commitment to better treatment options for patients worldwide with serious unmet medical needs.
Advancing transformative therapies across oncology, autoimmune, and fibrotic diseases — where patients have the fewest treatment options.
Addressing a broad range of cancers across diverse tumor types and lines of therapy — including cervical cancer, NSCLC, TNBC, and ovarian cancer.
Explore oncology programs
Targeting validated disease-modifying pathways in IPF, systemic sclerosis, and related conditions with significant unmet medical need.
Explore autoimmune programsLeveraging biologics and small molecules to target disease pathways with precision — from monoclonal antibodies to next-generation ADCs.
A next-generation checkpoint inhibitor designed to enhance anti-tumor immune responses across multiple cancer types.
Learn more
TROP2 and FRα targeted ADCs enabling precise delivery of cytotoxic payloads to tumor cells with reduced systemic toxicity.
Learn more
An FDA-approved small molecule being investigated for novel oncology indications through innovative repurposing strategies.
Learn moreStrong partnerships with academic institutions, biotechnology companies, and global development partners are essential to accelerating transformative medicines.
We are actively seeking partnerships with companies, academic institutions, and investors who share our commitment to transforming the lives of patients with serious diseases.